viernes, 3 de febrero de 2017

Sustiva (efavirenz) label was recently revised

Govdelivery template
HIV Masthead

The Sustiva (efavirenz) label was recently revised. The following sections in the Prescribing Information and Patient Counseling Information were update to include information about catatonia. 
  • WARNINGS AND PRECAUTIONS subsection 5.5 Psychiatric Symptoms 
  • ADVERSE REACTIONS subsection 6.2 Postmarketing Experience 
The updated label will soon be available drugs@fda or DailyMed

No hay comentarios:

Publicar un comentario